News

The capsules are the generic version of Wyeth’s Effexor XR capsules, which are used in the treatment of major depressive disorder and social anxiety disorder. Mylan is launching

Pfizer and Zhejiang Hisun Pharmaceuticals will explore a potential business collaboration focused on manufacturing cooperation to deliver and commercialize medicines through a local and global sales and marketing

Confab is a Montreal-based pharmaceutical manufacturing company with licenses from both FDA and European regulatory bodies, as well as certain Asian countries to manufacture drugs for human use.

XBiotech’s True Human monoclonal antibody, which blocks pathologic inflammatory responses, is being developed to treat diseases such as cancer, atherosclerosis and diabetes. C3i provides a solution to meet

Relovair is a once-daily inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) combination treatment, comprising fluticasone furoate and vilanterol (FF/VI), currently under development for the treatment of COPD and asthma. The

The agreement covers nine neglected tropical diseases (NTDs) – kinetoplastid diseases (leishmaniass, Chagas disease, and human African trypanosomiasis), helminth infections (lymphatic filariasis, onchocerciasis, and soil-transmitted helminthiasis) and dracunculiasis,

Gene expression data from human tumor samples indicate that both CSN5 and WEE1 genes promote tumor cell growth and cancer pathogenesis. WEE1 is a tyrosine kinase that regulates

Now with 451 kinase assays in the scanMAX assay panel, which will be available for global customers by mid-June 2011, DiscoveRx will continue to offer kinase panel for

PF-01367338, an oral and IV Poly (ADP-ribose) polymerase (PARP) inhibitor, is currently in Phase 1/2 development for solid tumors. The program is supplemented by two ongoing trials, currently